Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EAN 2026 | One big question with Piero Barbanti: what migraine advance could transform care within 3 years?

Piero Barbanti • 1 Jul 2026
EAN 2026
Headache Antibodies Fremanezumab

Piero Barbanti, MD, PhD, IRCCS San Raffaele Pisana, Rome, Italy, discusses the key advances in migraine that could transform care in the next three years. Prof. Barbanti highlights advances in the management of chronic migraine, such as treating earlier to prevent the progression of migraine. This interview took place at the 12th Congress of the European Academy of Neurology (EAN) in Geneva, Switzerland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Piero Barbanti

Treating migraine in women with a multidisciplinary approach
3:20
Treating migraine in women with a multidisciplinary approach
Piero Barbanti • 2 Apr 2025
Efficacy and tolerability of fremanezumab in the prevention of episodic and chronic migraine
3:33
Efficacy and tolerability of fremanezumab in the prevention of episodic and chronic migraine
Piero Barbanti • 2 Apr 2025
Understanding the I-GRAINE registry: bridging knowledge and daily practice in migraine care
2:13
Understanding the I-GRAINE registry: bridging knowledge and daily practice in migraine care
Piero Barbanti • 2 Apr 2025
Should CGRP antagonists be the first line of treatment for patients with migraine?
2:30
Should CGRP antagonists be the first line of treatment for patients with migraine?
Piero Barbanti • 2 Apr 2025

Related Videos

Why permanent standard time may be better for sleep and health
2:10
Why permanent standard time may be better for sleep and health
Karin Johnson • 16 Jun 2026
Spontaneous intracranial hypotension: insights from a session at EAN 2026
4:31
Spontaneous intracranial hypotension: insights from a session at EAN 2026
Rigmor Højland Jensen • 28 Jun 2026
Optimizing outcomes for patients with migraine who have a partial response to eptinezumab
2:16
Optimizing outcomes for patients with migraine who have a partial response to eptinezumab
Alessandro Visentini • 27 Jun 2026
PACAP-38 is increased in the tear fluid of patients with migraine
1:50
PACAP-38 is increased in the tear fluid of patients with migraine
Marina Romozzi • 27 Jun 2026
The content of VJNeurology is intended for healthcare professionals